A Phase II Study of JNJ-212082 (Abiraterone Acetate) in Metastatic Castration Resistant Prostate Cancer Patients Who Are Chemotherapy-Naive
Phase of Trial: Phase II
Latest Information Update: 25 Oct 2017
At a glance
- Drugs Abiraterone acetate (Primary) ; Prednisolone
- Indications Prostate cancer
- Focus Therapeutic Use
- Sponsors Janssen Research & Development
- 31 Aug 2018 Biomarkers information updated
- 02 Feb 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 26 Sep 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.